Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.

May 09, 2025

Vol.51 No.18

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Clinical

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pfizer Inc. on April 26 announced results from the pivotal phase III CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard-of-care Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Johnson & Johnson on April 26 announced new data from cohort 2 of the pivotal phase IIB SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

Zongertinib, a human epidermal growth factor receptor 2 targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer that harbored a HER2 mutation, according to results from the phase IA/IB Beamion LUNG-1 trial.

May 02, 2025

Vol.51 No.17

Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer

YOU MAY BE INTERESTED IN

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer

YOU MAY BE INTERESTED IN

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

Never miss an issue!

Login

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child